First in Human Study of Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis

Trial Profile

First in Human Study of Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Pulmonary alveolar proteinosis
  • Focus Adverse reactions; First in man
  • Acronyms PioPAP
  • Most Recent Events

    • 31 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top